不同剂量瑞舒伐他汀治疗急性冠脉综合征合并糖尿病患者的早期疗效及不良反应

发布时间：2018-04-11 04:23

本文选题：急性冠脉综合征 + 糖尿病　；参考：《实用医学杂志》2017年09期

【摘要】：目的:观察急性冠脉综合征(ACS)合并糖尿病患者应用不同剂量的瑞舒伐他汀治疗短期血脂达标情况及安全性。方法:回顾性分析2014年1月至2015年6月入住我院的ACS合并糖尿病患者99例,根据每晚服用瑞舒伐他汀的剂量分为5和10 mg组,其中5 mg组47例,10 mg组52例。记录入院时及治疗1个月后两组患者的血脂水平及肝、肾功能、MACE事件等,并计算两组患者的血脂达标率。结果:(1)治疗1个月后,两组患者TC、TG、LDL-C较入院时均明显下降(P0.05),其中10 mg组较5 mg组降低更明显(P0.05),血脂达标率更高(P0.05),而HDL-C差异无统计学意义。(2)10 mg组MACE事件发生率显著低于5 mg组,且两组患者均无严重药物不良反应发生。结论:10 mg瑞舒伐他汀能显著降低ACS合并糖尿病患者的血脂水平,减少MACE事件的发生,且较为安全。
[Abstract]:Aim: to observe the efficacy and safety of different doses of rosuvastatin in the treatment of acute coronary syndrome (ACS) patients with diabetes mellitus.Methods: 99 patients with ACS complicated with diabetes mellitus admitted to our hospital from January 2014 to June 2015 were analyzed retrospectively. According to the dosage of resuvastatin every night, they were divided into 5 and 10 mg groups, including 47 cases in 5 mg group and 52 cases in 10 mg group.The serum lipid level, liver and renal function and Mace events were recorded at admission and one month after treatment, and the rate of blood lipids reached the standard in both groups was calculated.Results after one month of treatment, the LDL-C of TCU TGG in both groups was significantly lower than that in admission, especially in 10 mg group and 5 mg group. The blood lipid rate was higher than that in 5 mg group. However, the incidence of MACE events in 10 mg group was significantly lower than that in 5 mg group, and the incidence of MACE events in 10 mg group was significantly lower than that in 5 mg group, and the incidence of MACE events in 10 mg group was significantly lower than that in 5 mg group.There were no serious adverse drug reactions in both groups.Conclusion Risuvastatin 10 mg can significantly reduce the level of blood lipids and decrease the incidence of MACE events in patients with ACS and diabetes mellitus.
【作者单位】：天津医科大学第二医院心脏科;
【分类号】：R541.4;R587.1

【共引文献】